Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes
PaperCitations, authors & open-access status
Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 80 citations, 2022 year and green oa status.
80
Citations
2022
Year
green
OA Status